The global pharmaceutical contract development market is expected to grow at a CAGR of ~6.9% from 2020 to reach ~181.0 billion by 2027. The growth of this market is primarily attributed to growing demand for generics and specialty medicines, increasing awareness for biological therapies, rapidly growing investments in R&D & manufacturing technologies by CDMOs, growing nuclear medicine sector and advancing cell & gene therapies. However, factors such as lack of skilled professionals and IPR issues are expected to hinder the growth of the market.
The global pharmaceutical contract development market study provides market data for-by services (Pharmaceutical manufacturing services, drug development services, biologics manufacturing services), by end users (Big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies and other end users). The study also evaluates industry competitors and analyses the market at a regional and country level.
By services, the biologics manufacturing services are projected to grow at the highest rate during the forecast period. The growth of this segment is mainly attributed to rapidly increasing demand for vaccines and biosimilar products.
By end users, big pharmaceutical companies segment dominated the pharmaceutical contract development market in 2020. The large share of this segment is mainly attributed moving shift towards contract development and manufacturing, increasing demand for end-to-end services, increasing need to regulate costs and pipelining changes.
This research report analyses major geographies and provides a comprehensive analysis of North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, India, Japan, and RoAPAC), Rest of the world (Latin America, and Middle East & Africa). North America commanded largest market share of pharmaceutical contract development market, by region. The largest share is attributed to large number of clinical trials, presence of leading pharmaceutical companies and large API production base. APAC is expected to exhibit highest CAGR in the forecast period. The growth of this regional market is mainly driven by government initiatives, increasing relevance of off-patent drugs, growing manufacturing sector, skilled professionals in these countries.
The major players operating in the pharmaceutical contract development market are
- Thermo Fisher Scientific Inc. (US)
- Catalent Inc. (US)
- Lonza Group Ltd. (Switzerland)
- Recipharm AB (Sweden)
- Vetter Pharma International GmbH (Germany)
- FAMAR Health Care Services (France)
- AbbVie Inc. (US)
- Aenova Group (Germany)
- Almac Group (UK)
- Siegfried Holding AG (Switzerland)
- Evonik Industries AG (Germany)
- WuXi AppTec (China)
- Samsung BioLogics (South Korea)
- Boehringer Ingelheim International GmbH (Germany)
- Cambrex Corporation (US)
- CordenPharma International (Germany)
- Albany Molecular Research Inc. (AMRI) (US)
- FUJIFILM Corporation (Japan)
- Piramal Pharma Solutions (India)
- Baxter International Inc. (US)
- Eurofins Scientific (Germany)
- BioVectra (Canada)
- Jubilant Life Science (India)
- NextPharma (UK)
- Delpharm (France)